Company: DRTSW
Filing Date: 2025-04-28
Form Type: 424B5
Source: 0001213900-25-035799
Chunk: 61

Company: Alpha Tau Medical Ltd.
Filing Date: 2025-04-28
Form: 424B5
Chunk 61
---
 security of the securities that we will offer pursuant hereto
will depend on a number of factors that may be relevant as of the time of offer. See “Plan of Distribution.”

<div align='center'>4

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS</div>

This prospectus contains
forward-looking statements that involve substantial risks and uncertainties. All statements other than statements of historical facts
contained in this prospectus, including statements regarding our future financial position, business strategy and plans and objectives
of management for future operations, are forward-looking statements. In some cases, you can identify forward-looking statements by terminology
such as “believe,” “may,” “estimate,” “continue,” “anticipate,” “intend,”
“should,” “plan,” “expect,” “predict,” “potential” or the negative of these
terms or other similar expressions. Forward-looking statements include, without limitation, our expectations concerning the outlook for
our business, productivity, plans and goals for future operational improvements and capital investments, operational performance, future
market conditions or economic performance and developments in the capital and credit markets and expected future financial performance.

Forward-looking
statements involve a number of risks, uncertainties and assumptions, and actual results or events may differ materially from those projected
or implied in those statements. Important factors that could cause such differences include, but are not limited to:

| ● | We have incurred significant losses since inception, and expects to incur losses over the next several years and may not be able to achieve or sustain revenues or profitability in the future; |

| ● | We may need substantial additional funding, and if we are unable to raise capital when needed, we could be forced to delay, reduce or terminate the development of the Alpha DaRT technology or other product discovery and development programs or commercialization efforts; |

| ● | Our limited operating history may make it difficult for you to evaluate the success of our business to date and to assess its future viability; |

| ● | Our approach to the development of its proprietary Alpha DaRT technology represents a novel approach to radiation therapy, which creates significant and potentially unpredictable challenges for us; |

| ● | The commercial success of our Alpha DaRT technology, if authorized or certified for commercial sale, will depend in part upon public perception of radiation therapies, and to a lesser extent, radiopharmaceuticals, and the degree of their market acceptance by physicians, patients, healthcare payors and others in the medical community; |

| ● | The ongoing COVID-19 pandemic could